C12N 2310/3515
Lipophilic moiety
Official title: Lipophilic moiety, e.g. cholesterol
C12N2310/3515 (Lipophilic moiety) appears on 885 US grants and 1,652 published applications in this corpus.
Search patents in C12N- Granted patents
- 885
- Published applications
- 1,652
- Assignees
- 400
- Inventors
- 1,949
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 3 | 0 |
| 1998 | 6 | 0 |
| 1999 | 6 | 0 |
| 2000 | 6 | 0 |
| 2001 | 7 | 1 |
| 2002 | 2 | 1 |
| 2003 | 2 | 8 |
| 2004 | 4 | 10 |
| 2005 | 3 | 14 |
| 2006 | 3 | 14 |
| 2007 | 2 | 17 |
| 2008 | 1 | 15 |
| 2009 | 9 | 39 |
| 2010 | 17 | 46 |
| 2011 | 20 | 46 |
| 2012 | 38 | 53 |
| 2013 | 36 | 48 |
| 2014 | 29 | 58 |
| 2015 | 65 | 68 |
| 2016 | 50 | 97 |
| 2017 | 49 | 74 |
| 2018 | 62 | 78 |
| 2019 | 62 | 87 |
| 2020 | 52 | 99 |
| 2021 | 69 | 122 |
| 2022 | 69 | 127 |
| 2023 | 50 | 142 |
| 2024 | 53 | 161 |
| 2025 | 69 | 132 |
| 2026 | 37 | 95 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy6 Oct 2026US 12,753,407 B2Phio Pharmaceuticals Corp.
- Huntingtin (HTT) iRNA agent compositions and methods of use thereof18 Aug 2026US 12,709,748 B2Alnylam Pharmaceuticals, Inc.
- Mannan binding lectin serine peptidase 2 (MASP2) IRNA compositions and methods of use thereof18 Aug 2026US 12,709,751 B2Alnylam Pharmaceuticals, Inc.
- Monocyte-specific aptamers and uses thereof for delivering therapeutic agents to heart11 Aug 2026US 12,702,716 B2Academia Sinica
- USP10 targeted self-deliverable siRNA compositions and methods for preventing or inhibiting fibrosis and/or scarring4 Aug 2026US 12,698,501 B2The Research Foundation for The State University of New York
- Modulating apolipoprotein (a) expression8 Oct 2026US 2026/0308584 A1Ionis Pharmaceuticals, Inc.
- Treatment of gpam related diseases and disorders8 Oct 2026US 2026/0308594 A1Empirico Inc.
- Extrahepatic delivery of double-stranded rna agents1 Oct 2026US 2026/0297574 A1Alnylam Pharmaceuticals, Inc.
- Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same1 Oct 2026US 2026/0297581 A1Aligos Therapeutics, Inc.
- Pcsk9 irna compositions and methods of use thereof1 Oct 2026US 2026/0297586 A1Alnylam Pharmaceuticals, Inc.
Most cited
By later US patents
- Lipid formulation340US 8,158,601 B2Alnylam Pharmaceuticals, Inc. · 2012
- Compositions and methods for inhibiting expression of Eg5 gene215US 7,718,629 B2Alnylam Pharmaceuticals, Inc. · 2010
- Aminoalcohol lipidoids and uses thereof207US 8,450,298 B2Massachusetts Institute of Technology · 2013
- Oligonucleotides conjugated to protein-binding drugs180US 6,656,730 B1Isis Pharmaceuticals, Inc. · 2003
- Compositions and methods for inhibiting expression of Huntingtin gene167US 7,320,965 B2Alnylam Pharmaceuticals, Inc. · 2008